- Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kd Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular LymphomaWang, Tingyu; Sun, Xiuhua; Qiu, Lihua; Su, Hang; Cao, Junning; Li, Zhiming; Song, Yuqin; Zhang, Li; Li, Dengju; Wu, Huijing; Zhang, Wei; Li, Junmin; Zhou, Keshu; Zhou, Hui; Yang, Yu; Li, Zhifeng; Cen, Hong; Cai, Zhen; Zhang, Zhihui; Fu, Weijun; Jie, Jin; Li, Fei; Wu, Weixin; Gu, Xuekui; Zhu, Weiliang; Liu, Lihong; Li, Zengjun; Yi, Shuhua; Bao, Hanying; Xu, Zusheng; Qiu, Lugui65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II StudyLyu, Fangfang; Cao, Junning; Wang, Tingyu; Sun, Xiuhua; Qiu, Lihua; Su, Hang; Li, Zhiming; Song, Yuqin; Zhang, Li; Li, Dengju; Wu, Huijing; Zhang, Wei; Li, Junmin; Zhou, Keshu; Zhou, Hui; Yang, Yu; Li, Zhifeng; Cen, Hong; Cai, Zhen; Zhang, Zhihui; Fu, Weijun; Jie, Jin; Li, Fei; Wu, Weixin; Gu, Xuekui; Zhu, Weiliang; Liu, Lihong; Li, Zengjun; Yi, Shuhua; Bao, Hanying; Xu, Zusheng; Qiu, Lugui65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell LymphomaLi, Zhiming; Yang, Haiyan; Cen, Hong; Huang, Rui; Cai, Zhen; Gu, Xuekui; Bao, Hanying; Xu, Zusheng; Xu, Zuhong63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA, 2021-12-11 To 2021-12-14.
会议论文
PI3K δ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
10阅读
